Rhenman & Partners Asset Management AB Buys 1,750 Shares of BioNTech SE (NASDAQ:BNTX)

Rhenman & Partners Asset Management AB boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 52,750 shares of the company’s stock after buying an additional 1,750 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in BioNTech were worth $6,011,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after purchasing an additional 74,119 shares during the period. SG Americas Securities LLC grew its stake in shares of BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after buying an additional 33,375 shares during the last quarter. Mirabaud & Cie SA purchased a new stake in shares of BioNTech in the fourth quarter worth approximately $684,000. Bank of New York Mellon Corp lifted its stake in shares of BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Finally, Vestcor Inc purchased a new position in BioNTech during the 3rd quarter valued at $784,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Down 4.3 %

Shares of BioNTech stock opened at $88.05 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market cap of $21.13 billion, a P/E ratio of -41.93 and a beta of 1.07. The firm’s 50 day moving average price is $108.81 and its 200-day moving average price is $112.88. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The business’s quarterly revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BNTX shares. HC Wainwright reduced their target price on BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a research note on Tuesday. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Truist Financial assumed coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Morgan Stanley dropped their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.